Advances in the clinical management of high-risk Wilms tumors. Review uri icon

Overview

abstract

  • Outcomes are excellent for the majority of patients with Wilms tumors (WT). However, there remain WT subgroups for which the survival rate is approximately 50% or lower. Acknowledging that the composition of this high-risk group has changed over time reflecting improvements in therapy, we introduce the authors' view of the historical and current approach to the classification and treatment of high-risk WT. For this review, we consider high-risk WT to include patients with newly diagnosed metastatic blastemal-type or diffuse anaplastic histology, those who relapse after having been initially treated with three or more different chemotherapeutics, or those who relapse more than once. In certain low- or low middle-income settings, socio-economic factors expand the definition of what constitutes a high-risk WT. As conventional therapies are inadequate to cure the majority of high-risk WT patients, advancement of laboratory and early-phase clinical investigations to identify active agents is urgently needed.

authors

  • Ortiz, Michael V.
  • Koenig, Christa
  • Armstrong, Amy E
  • Brok, Jesper
  • de Camargo, Beatriz
  • Mavinkurve-Groothuis, Annelies M C
  • Herrera, Thelma B Velasquez
  • Venkatramani, Rajkumar
  • Woods, Andrew D
  • Dome, Jeffrey S
  • Spreafico, Filippo

publication date

  • January 10, 2023

Research

keywords

  • Kidney Neoplasms
  • Wilms Tumor

Identity

Scopus Document Identifier

  • 85146184772

Digital Object Identifier (DOI)

  • 10.1002/pbc.30153

PubMed ID

  • 36625399

Additional Document Info

volume

  • 70

issue

  • 3